EMA grants PRIME eligibility for MEDI8897
5 February 2019 07:00 GMT EMA grants PRIME eligibility for potentialnext-generation RSV medicine MEDI8897 First EMA PRIME eligibility for AstraZeneca Eligibility based on positive primary analysis of thePhase IIb trial to evaluate the safety and efficacy of MEDI8897 AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the European Medicines Agency (EMA) has granted access to its PRIME (PRIority MEdicines) scheme for MEDI8897, an extended half-life respiratory syncytial virus (RSV) F monoclonal antibody (mAb) being developed for